GlassScriptPhysician profile
Joseph Acosta
NPI 1710976915
$32,827.41
in general payments reported to CMS, 2019-2025
79 companies · $5,190 in 2025
The $5,190 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,181 · 2020: $2,938 · 2021: $3,811 · 2022: $5,229 · 2023: $5,792 · 2024: $4,686 · 2025: $5,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,510.98 |
| Education | $157.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,400.15 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $2,650.13 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Ucb, INC. | $1,947.51 | 2019-2025 | Briviact, Fintepla, Zilbrysq |
| Acadia Pharmaceuticals INC | $1,667.24 | 2019-2025 | Nuplazid, Daybue |
| Pfizer INC. | $1,411.22 | 2021-2025 | |
| Amgen INC. | $1,218.96 | 2019-2025 | Uplizna, Aimovig |
| Lundbeck LLC | $1,208.40 | 2019-2025 | Vyepti, Rexulti |
| Sunovion Pharmaceuticals INC. | $1,200.34 | 2019-2022 | |
| Genzyme Corporation | $1,131.18 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,125.02 | 2019-2025 | |
| Biogen, INC. | $904.08 | 2019-2025 | Leqembi, Vumerity, Tysabri |
| Allergan, INC. | $846.06 | 2019-2022 | |
| Lilly USA, LLC | $836.12 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Grifols USA, LLC | $807.16 | 2019-2025 | Gamunex-C |
| Argenx US, INC. | $713.56 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Acosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.